| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 23.335 | -2.175 | 4.996 | 4.040 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 23.336 | -2.174 | 4.996 | 4.040 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 3.478 | 3.609 | 1.855 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | 19.858 | -5.782 | 3.142 | 4.040 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit/Loss - EUR | 19.158 | -6.322 | 3.028 | 4.000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Oncovit New Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 47.407 | 31.338 | 34.373 | 37.783 | 20.158 | 19.776 | 19.338 | 19.398 | 40 | 40 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 4.964 | 25 | 3.640 | 7.613 | 7.466 | 7.324 | 7.162 | 7.184 | 0 | 0 |
| Cash | 42.443 | 31.313 | 30.733 | 30.170 | 12.692 | 12.452 | 12.176 | 12.213 | 40 | 40 |
| Shareholders Funds | 29.791 | 24.556 | 27.168 | 30.669 | 20.158 | 19.776 | 19.338 | 19.398 | 40 | 40 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 17.616 | 6.783 | 7.206 | 7.114 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncovit New Srl